L

Lyell Immunopharma

T cell therapies for solid tumors

Director or Senior Director - Investor Relations and Corporate Communications

PR & CommunicationsConfirmed live in the last 24 hours
Full-timeSouth San Francisco, CA, USA

About the Job

Requirements

  • A minimum of 10 years of experience in public relations, preferably investor relations, corporate communications, or media, plus at least 8 years of experience in management and leadership roles in mid- to large-size organizations for the Senior Director level.
  • A minimum of 7–9 years of experience in public relations, preferably investor relations, corporate communications, or media, plus at least 5–7 years of experience in management and leadership roles in mid- to large-size organizations for the Director level.
  • Experience in the biotechnology industry in investor relations and corporate communications, or experience as a sell-side analyst.
  • A track record of managing investor relations strategy and supporting significant initiatives such as financing, conference participation, and product launches.
  • The ability to tailor written and verbal communications to diverse audiences and define the company’s internal and external voices.
  • Executive leadership experience with familiarity in business or corporate development or operations.
  • Cross-functional experience leading through complexity and influencing and collaborating with multiple stakeholders across functions and organizational levels.
  • The ability to lead executive discussions, focus on detail, and think strategically.
  • The ability to prioritize and execute competing priorities in a fast-moving environment.
  • The ability to manage diverse objectives and shift between strategy and execution in a start-up environment.
  • The ability to use sound judgment in external communications.

Responsibilities

  • Collaborate with the C-suite and product teams to develop and execute a communications strategy for investors through quarterly filings, conference calls, investor conferences, and roadshows.
  • Ensure effective and consistent execution of the corporate communications strategy to maintain outreach to investors and analysts and keep the company’s strategy and progress top of mind.
  • Lead, develop, and execute a comprehensive strategic communications strategy and tactical plan to achieve investor relations objectives, evolving it as needed.
  • Partner with Finance and Legal to ensure investor-facing communications are robust, timely, accurate, and compelling.
  • Develop written materials such as key messages, frequently asked questions, and talking points for conference calls and investor and analyst events.
  • Train, advise, and develop spokespeople for media interviews, press conferences, and industry presentations, and prepare talking points and briefing documents.
  • Build relationships with analysts, investors, members of the press, influencers, and partners, including serving as an on-record spokesperson in accordance with the external communications strategy.
  • Partner with media, the identified public relations agency, and external partners to develop and execute campaigns and outreach programs and monitor brand activity.
  • Maintain a thorough understanding of the corporate strategy and the importance of each stakeholder segment to the corporate and scientific portfolio and messaging.
  • Manage daily proactive and responsive company communications, including devising a crisis communications strategy and rapid-response efforts.
  • Track developments and public announcements by competitors and peer companies.

Desired Qualifications

  • A bachelor’s degree in a scientific discipline; Communications, Marketing, or a related field may be considered with significant biotechnology industry experience.
  • A master’s degree.

About the Company

Lyell Immunopharma

T cell therapies for solid tumors

Lyell Immunopharma designs and develops adoptive T cell therapies to treat solid tumors. Its core approach is to genetically and epigenetically reprogram T cells (Gen-R and Epi-R) to better recognize and persist against cancer cells, addressing T cell exhaustion and loss of stemness. The company builds a diverse pipeline of treatment modalities targeting various solid tumor types, with a business model centered on licensing proprietary technologies or selling therapies to healthcare providers. Lyell aims to deliver curative cell therapies for solid tumors, leveraging a team of oncology and ACT experts to push beyond current cancer treatments.

Company size
201-500
Company stage
IPO
Headquarters
South San Francisco, CA
Founded
2018

Recently Posted Jobs

Explore more opportunities at Lyell Immunopharma

See more jobs